Effects of SA13353, a transient receptor potential vanilloid 1 agonist, on leukocyte infiltration in lipopolysaccharide-induced acute lung injury and ovalbumin-induced allergic airway inflammation

J Pharmacol Sci. 2010;112(4):487-90. doi: 10.1254/jphs.09295sc. Epub 2010 Mar 30.

Abstract

We recently demonstrated that SA13353, a transient receptor potential vanilloid 1 (TRPV1) agonist, reduced the severity of the symptoms of kidney injury, arthritis, and encephalomyelitis in disease models. Here, we investigated the effects of orally administered SA13353 on leukocyte infiltration in lipopolysaccharide (LPS)-induced acute lung injury and ovalbumin-induced allergic airway inflammation. In LPS-induced lung injury, SA13353 attenuated neutrophil infiltration and the increase of TNF-alpha and CINC-1 levels. In allergic airway inflammation, SA13353 tended to inhibit leukocyte infiltration and attenuated the increase of IL-4 and IL-12p40. These results suggest that somatosensory TRPV1 may play an anti-inflammatory role in lung inflammation.

MeSH terms

  • Animals
  • Inflammation / chemically induced*
  • Leukocytes / cytology*
  • Lipopolysaccharides / toxicity*
  • Lung / drug effects*
  • Lung / pathology
  • Mice
  • Ovalbumin / toxicity*
  • Pyridines / pharmacology*
  • TRPV Cation Channels / agonists*
  • Trachea / drug effects*
  • Trachea / pathology
  • Urea / analogs & derivatives*
  • Urea / pharmacology

Substances

  • 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea
  • Lipopolysaccharides
  • Pyridines
  • TRPV Cation Channels
  • TRPV1 protein, mouse
  • Urea
  • Ovalbumin